Platinum

Generic Name: Platinum

Drug Type: Small Molecule

Chemical Formula: Pt

CAS Number: 7440-06-4

Unique Ingredient Identifier: 49DFR088MY

Background: Platinum is under investigation for the treatment of Metastatic Breast Cancer, Non-small Cell Lung Cancer, Gastric Large Cell Neuroendocrine Carcinoma, Colorectal Large Cell Neuroendocrine Carcinoma, and Pancreatic Large Cell Neuroendocrine Carcinoma, among others. Platinum has been investigated for the treatment and supportive care of Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Primary Cancer, Non Small Cell Lung Cancer, and Primary Peritoneal Carcinoma, among others.

Clinical Trials

Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma

Phase 1

Recruiting

Conditions: Mesothelioma

Interventions: Drug: Platinum cisplatin or carboplatin and pemetrexed chemotherapy plus durvalumab/tremelimumab
Drug: Durvalumab / tremelimumab

First Posted Date: 2023-07-06

Last Posted Date: 2024-08-26

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 52

Registration Number: NCT05932199

Locations: 🇺🇸
Baylor St Lukes, Houston, Texas, United States
🇺🇸
Duke Cancer Institute, Durham, North Carolina, United States

A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC

Phase 2

Active, not recruiting

Conditions: SCLC

Interventions: Drug: PM8002
Drug: Platinum
Drug: Etoposide

First Posted Date: 2023-05-06

Last Posted Date: 2025-03-12

Lead Sponsor: Biotheus Inc.

Target Recruit Count: 50

Registration Number: NCT05844150

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, China
🇨🇳
Jilin Cancer Hospital, Changchun, China
🇨🇳
The First Affiliated Hospital of Chongqing Medical University, Chongqing, China

and more 14 locations

A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)

Phase 2

Recruiting

Conditions: Non Small Cell Lung Cancer
Non Small Cell Lung Cancer Metastatic
Non-small Cell Carcinoma
NSCLC
NSCLC Stage IV

Interventions: Radiation: L-SABR
Biological: Anti-PD-(L)1 based immunotherapy
Drug: Platinum based chemotherapy

First Posted Date: 2022-12-20

Last Posted Date: 2025-05-20

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 68

Registration Number: NCT05657873

Locations: 🇺🇸
BAPTIST ALLIANCE - MCI (Data Collection Only), Miami, Florida, United States
🇺🇸
Memorial Sloan Kettering at Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey, United States

and more 6 locations

Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.

Phase 2

Recruiting

Conditions: Esophageal Neoplasms
Digestive System Neoplasms
Esophageal Diseases

Interventions: Drug: camrelizumab
Drug: Paclitaxel drugs
Drug: Platinum drug
Radiation: Radiation

First Posted Date: 2022-11-21

Last Posted Date: 2023-10-19

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 75

Registration Number: NCT05624099

Locations: 🇨🇳
Fujian Cancer Hospital, Fuzhou, China

Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab

Phase 2

Recruiting

Conditions: Non-small-cell Lung Cancer Patients

Interventions: Drug: Single-agent chemotherapy
Drug: Durvalumab
Drug: Olaparib tablet
Drug: Platinum doublet chemotherapy

First Posted Date: 2022-10-05

Last Posted Date: 2022-10-05

Lead Sponsor: Fondazione Ricerca Traslazionale

Target Recruit Count: 176

Registration Number: NCT05568212

Locations: 🇮🇹
Istituti Fisioterapici Ospitalieri- Ifo - Istituto Regina Elena, Roma, RM, Italy

An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer

Phase 2

Recruiting

Conditions: Resectable Stage IIA to IIIB Non-small Cell Lung Cancer

Interventions: Drug: Nivolumab
Drug: Platinum Doublet
Radiation: (8gy x 3)

First Posted Date: 2022-08-12

Last Posted Date: 2024-02-15

Lead Sponsor: Montefiore Medical Center

Target Recruit Count: 52

Registration Number: NCT05500092

Locations: 🇺🇸
Montefiore Medical Center-Albert Einstein College of Medicine, Bronx, New York, United States

Tislelizumab in Combination With Chemotherapy for Conversion Therapy of Locally Nonresectable ESCC

Phase 2

Conditions: Esophageal Squamous Cell Carcinoma
Locally Advanced Carcinoma

Interventions: Drug: Tislelizumab
Drug: 5-FU
Drug: cis Platinum

First Posted Date: 2022-07-21

Last Posted Date: 2022-07-21

Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University

Target Recruit Count: 17

Registration Number: NCT05469061

Locations: 🇨🇳
Jiangsu Provincial People's Hospital, Nanjing, Jiangsu, China

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Phase 3

Recruiting

Conditions: Platinum-resistant Ovarian Cancer
Platinum-refractory Ovarian Cancer
Primary Peritoneal Cancer
Fallopian Tube Cancer
Endometrioid Ovarian Cancer
High-grade Serous Ovarian Cancer
Ovarian Clear Cell Carcinoma

Interventions: Drug: Bevacizumab (or biosimilar)
Biological: olvimulogene nanivacirepvec

First Posted Date: 2022-03-16

Last Posted Date: 2025-05-14

Lead Sponsor: Genelux Corporation

Target Recruit Count: 186

Registration Number: NCT05281471

Locations: 🇺🇸
The University of South Alabama, Mitchell Cancer Institute, Mobile, Alabama, United States
🇺🇸
University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸
City of Hope, Duarte, California, United States

and more 27 locations